ASTX660

A non-peptidomimetic inhibitor of IAP protein-peptide interactions

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥587.00

470.00

- +
5mg

￥2175.00

1740.00

- +
10mg

￥3775.00

3020.00

- +
25mg

￥5937.00

4750.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

ASTX660 is an inhibitor of inhibitor of apoptosis (IAP) protein-peptide interactions.¹ It inhibits the protein-peptide interaction between the IAP1 and XIAP BIR3 domains with a Smac-derived peptide in cell-free assays (IC₅₀s = <40 and 12 nM, respectively). ASTX660 inhibits the protein-protein interaction between XIAP and caspase-9 in HEK293 cells (EC₅₀ = 2.8 nM) and induces displacement of Smac from XIAP in A375 melanoma cells. It induces apoptosis in MDA-MB-231, A375, and SK-MEL-28 cells in a TNF-α-dependent manner. In vivo, ASTX660 (20 mg/kg) reduces tumor growth in MDA-MB-231 breast cancer and A375 melanoma mouse xenograft models.

1.Ward, G.A., Lewis, E.J., Ahn, J.S., et al.ASTX660, a novel non-peptidomimetic antagonist of cIAP1/2 and XIAP, potently induces TNFα-dependent apoptosis in cancer cell lines and inhibits tumor growthMol. Cancer Ther.17(7)1381-1391(2018)